James R W, Borghini I
Département de médecine, Hôpital cantonal, Genève.
Ther Umsch. 1990 Jun;47(6):448-55.
A full, clinical appreciation of blood cholesterol levels necessitates recognition of the divergent influences of cholesterol associated with low density lipoprotein (atherogenic) and high density lipoproteins (HDL, anti-atherogenic) on the atherosclerotic process. Convincing evidence now exists to show that raising HDL-cholesterol levels reduces the incidence of cardiovascular disease, thus providing a firm rationale for therapeutic measures designed to favourably modify its plasma concentrations. In this respect, association of lower HDL-cholesterol levels with an unhealthy life style (smoking, lack of exercise, obesity) is of particular relevance. Whilst still a subject of discussion, available data strongly support the inclusion of HDL-cholesterol measurements when establishing plasma lipid profiles.
要全面、临床地评估血液胆固醇水平，就必须认识到与低密度脂蛋白（致动脉粥样硬化）和高密度脂蛋白（HDL，抗动脉粥样硬化）相关的胆固醇对动脉粥样硬化进程的不同影响。现在有确凿的证据表明，提高HDL胆固醇水平可降低心血管疾病的发病率，从而为旨在有利地改变其血浆浓度的治疗措施提供了坚实的理论依据。在这方面，较低的HDL胆固醇水平与不健康的生活方式（吸烟、缺乏运动、肥胖）之间的关联尤为重要。虽然这仍是一个讨论的话题，但现有数据有力地支持在建立血脂谱时纳入HDL胆固醇测量。
